The high-yield notes are due 2033

Davis Polk advised the representative of the several initial purchasers in connection with a Rule 144A / Regulation S offering by Insulet Corporation of $450 million aggregate principal amount of its 6.50% senior notes due 2033.

Insulet, headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod insulin management system provides a unique alternative to traditional insulin delivery methods.

The Davis Polk capital markets team included partner Yasin Keshvargar, counsel Michael Stromquist and associate Nicole (Nikki) Williams. The tax team included partner Michael Mollerus and associate Alanna Phillips. Partner David R. Bauer and associates Nazli Ungan and Francesca Masella provided intellectual property advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post